Abstract:Cytosine base editors (CBEs), combining cytidine deaminases with the Cas9 nickase (nCas9), enable targeted C-to-T conversions in genomic DNA and are powerful genome-editing tools used in biotechnology and medicine. However, the overexpression of cytidine deaminases in vivo leads to unexpected potential safety risks, such as Cas9-independent off-target effects. This risk makes the development of deaminase off switches for modulating CBE activity an urgent need. Here, we report the repurpose of four virus-derived anti-deaminases (Ades) that efficiently inhibit APOBEC3 deaminase-CBEs. We demonstrate that they antagonize CBEs by inhibiting the APOBEC3 catalytic domain, relocating the deaminases to the extranuclear region or degrading the whole CBE complex. By rationally engineering the deaminase domain, other frequently used base editors, such as CGBE, A&CBE, A&CGBE, rA1-CBE and ABE8e, can be moderately inhibited by Ades, expanding the scope of their applications. As a proof of concept, the Ades in this study dramatically decrease both Cas9-dependent and Cas9-independent off-target effects of CBEs better than traditional anti-CRISPRs (Acrs). Finally, we report the creation of a cell type-specific CBE-ON switch based on a microRNA-responsive Ade vector, showing its practicality. In summary, these natural deaminase-specific Ades are tools that can be used to regulate the genome-engineering functions of BEs. Anti-deaminases can inhibit APOBEC3, a component of cytosine base editors. Here Zhanjun Li and colleagues repurposed anti-deaminase proteins derived from viruses to inhibit base editors for use in efficient regulation of base editors' activity in gene modification and therapeutic applications.

AcrIIA5 Suppresses Base Editors and Reduces Their Off-Target Effects

Inhibition of Base Editors with Anti-Deaminases Derived from Viruses.

Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing

An APOBEC3A-Cas9 Base Editor with Minimized Bystander and Off-Target Activities

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells.

Disabling Cas9 by an anti-CRISPR DNA mimic

Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors

Precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions

Re-engineering the adenine deaminase TadA-8e for efficient and specific CRISPR-based cytosine base editing

Cas9-orthologue-mediated cytosine and adenine base editors recognizing NNAAAA PAM sequences

Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing

Expanding the Genome-Targeting Scope and the Site Selectivity of High-Precision Base Editors

Eliminating Base-Editor-induced Genome-Wide and Transcriptome-Wide Off-Target Mutations

ACBE, a new base editor for simultaneous C-to-T and A-to-G substitutions in mammalian systems

Two Compact Cas9 Ortholog-Based Cytosine Base Editors Expand the DNA Targeting Scope and Applications In Vitro and In Vivo

Base Editing with a Cpf1–cytidine Deaminase Fusion

Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing

A Broad-Spectrum Inhibitor of CRISPR-Cas9

Rational Design of Enhanced Nme2Cas9 and Nme2 Cas9 Nucleases and Base Editors

Decreasing predictable DNA off-target effects and narrowing editing windows of adenine base editors by fusing human Rad18 protein variant